Literature DB >> 36187513

Correlation Of Bi-Rads 4 Subcategories Breast Lesions On Tomosynthesis And Histopathological Examination With P63 Immunohistochemistry Expression.

H Lalchhanhimi1, V Pavithra2, Dev Bhawna1, Sheela Chinnappan1, Harini Gnanavel1, Sai Venkata1.   

Abstract

Mammography is considered to be the gold standard for screening and detection of breast malignancies. Among different biochemical markers used to detect carcinoma of breasts, p63 has been widely popularized for its effectiveness in the detection of myoepithelial cells which are an important indicator of breast benignity. In this study, we plan to statistically analyze and correlate the Breast Imaging Reporting and Data System (BI-RADS) 4 subcategories grading on mammogram imaging with p63 immunostaining. A total of 80 patients were taken into the study within a period of two years (2016-2018) after ensuring the inclusion and exclusion criteria. They were further sorted into different BI-RADS 4 subcategories, i.e., taking into consideration X-ray mammogram and tomosynthesis findings, 57 samples were categorized as low suspicion (BI-RADS 4A), while 12 were classified as intermediate (BI-RADS 4B), and the remaining 11 samples were categorized as highly suspicious (BI-RADS 4C). Although considered to be leaning toward malignancy, a BI-RADS reading of 4 (namely 4A-low suspicion, 4B-moderate suspicion, and 4C-high suspicion for malignancy) needs further evaluation for accurate diagnosis. There have been cases within our own observation where a lesion that is highly suspicious of malignancy has turned out to be a benign finding. Further, evaluating the expression of a p63 marker can help prevent mutilating surgeries for indeterminate lesions. The present study has been conducted to study the correlation of tomosynthesis grading of lesions that has been categorized from low-to-high suspicion, with a p63 immunostaining pattern in these lesions.
© The Author(s), under exclusive licence to Indian Association of Surgical Oncology 2022.

Entities:  

Keywords:  BI-RADS 4; Immunohistochemistry; Malignancy; Myoepithelial; p63

Year:  2022        PMID: 36187513      PMCID: PMC9515276          DOI: 10.1007/s13193-022-01530-w

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN: 0975-7651


  15 in total

Review 1.  Taking advantage of basic research: p63 is a reliable myoepithelial and stem cell marker.

Authors:  Jorge S Reis-Filho; Fernando C Schmitt
Journal:  Adv Anat Pathol       Date:  2002-09       Impact factor: 3.875

Review 2.  The usefulness of p63 as a marker of breast myoepithelial cells.

Authors:  Anna Batistatou; Dimitrios Stefanou; Evdokia Arkoumani; Niki J Agnantis
Journal:  In Vivo       Date:  2003 Nov-Dec       Impact factor: 2.155

Review 3.  Significance of immunohistochemistry in breast cancer.

Authors:  Dana Carmen Zaha
Journal:  World J Clin Oncol       Date:  2014-08-10

Review 4.  Correlation between imaging and molecular classification of breast cancers.

Authors:  M Boisserie-Lacroix; G Hurtevent-Labrot; S Ferron; N Lippa; H Bonnefoi; G Mac Grogan
Journal:  Diagn Interv Imaging       Date:  2013-07-15       Impact factor: 4.026

Review 5.  Immunohistochemical markers as predictive tools for breast cancer.

Authors:  R A Walker
Journal:  J Clin Pathol       Date:  2007-11-23       Impact factor: 3.411

6.  p63 expression in benign and malignant breast lesions.

Authors:  D Stefanou; A Batistatou; A Nonni; E Arkoumani; N J Agnantis
Journal:  Histol Histopathol       Date:  2004-04       Impact factor: 2.303

7.  p40 (ΔNp63) expression in breast disease and its correlation with p63 immunohistochemistry.

Authors:  Sang Kyum Kim; Woo Hee Jung; Ja Seung Koo
Journal:  Int J Clin Exp Pathol       Date:  2014-02-15

8.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

9.  Immunohistochemical distinction of invasive from noninvasive breast lesions: a comparative study of p63 versus calponin and smooth muscle myosin heavy chain.

Authors:  Robert W Werling; Harry Hwang; Hadi Yaziji; Allen M Gown
Journal:  Am J Surg Pathol       Date:  2003-01       Impact factor: 6.394

10.  Immunoexpression of P63 and SOX2 in triple-negative breast cancers, Indonesia.

Authors:  Reno K Kamarlis; Muhammad Nd Lubis; Bethy S Hernowo; Azmi S Kar
Journal:  F1000Res       Date:  2017-09-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.